Search Results
10
Everything
Longeveron® to Present at the 37th Annual Roth Conference
March 05, 2025 09:25 ET
|
Longeveron
Longeveron to present at the Roth investor conference taking place March 17-18, 2025. Company fireside chat Tuesday, March 18th at 9:00am PT.
Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update
February 28, 2025 16:04 ET
|
Longeveron
Longeveron announces 2024 financial results and provides business update. Pivotal Phase 2b clinical trial achieves 90% enrollment.
Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025
February 21, 2025 08:30 ET
|
Longeveron
Longeveron to report full-year 2024 financial results and provide a business update on Friday, February 28, 2025 after the U.S. financial markets close.
Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™
February 18, 2025 09:25 ET
|
Longeveron
WHO approved generic name laromestrocel for stem cell therapy Lomecel-B, being developed as potential treatment for Alzheimer's disease and HLHS.
Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025
February 14, 2025 09:05 ET
|
Longeveron
Longeveron to present at the Emerging Growth Virtual Conference taking place February 18-19, 2025.
Longeveron to Present at Biotech Showcase 2025
December 18, 2024 09:10 ET
|
Longeveron
Longeveron Chief Executive Officer Wa’el Hashad will give a corporate presentation at Biotech Showcase, being held January 13-15, 2025.
Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024
December 02, 2024 09:05 ET
|
Longeveron
Longeveron will participate in the Emerging Growth Virtual Conference with company presentation December 5th at 12:00pm ET.
Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024 16:05 ET
|
Longeveron
Longeveron reports 3Q24 financial results. Pivotal Phase 2b clinical trial in HLHS achieves 80% enrollment. Positive Phase 2 data for Alzheimer's disease.
Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
October 27, 2024 15:10 ET
|
Longeveron
Longeveron reports positive long-term transplant-free survival (100% survival) data from a multi-year study in Hypoplastic Left Heart Syndrome (HLHS)
Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
October 09, 2024 09:05 ET
|
Longeveron
Longeveron® Lomecel-B 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society Mtg.